BCRX vs CSL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BCRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCRX and CSL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCRX and CSL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).

Full BCRX guide

Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. It operates through two segments: Carlisle Construction Materials (CCM), which makes single-ply roofing membranes (EPDM rubber, TPO, and PVC), polyiso insulation, and metal roofing and wall systems, and Carlisle Weatherproofing Technologies (CWT), which makes waterproofing, air and vapor barriers, sealants, spray polyurethane foam, coatings, and related moisture-protection products. The company earns most of its revenue from commercial construction, and within that, a large share comes from re-roofing (replacing aging roofs), which is more stable than new construction because roofs wear out on a predictable cycle regardless of the economy.

Full CSL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCRX drivers: ORLADEYO revenue growth and operating leverage; Navenibart and the Astria pipeline bet.
• CSL drivers: Commercial re-roofing replacement cycle; Margin expansion and pure-play focus.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard. For CSL, carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BCRX if you believe its drivers more; CSL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCRX and CSL guides.

BCRX. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on GAAP earnings, since 2026 results were dominated by a roughly $698 million one-time non-cash acquired-IPR&D charge from the Astria deal that produced a large GAAP operating loss. On a non-GAAP basis the company reported operating profit and reaffirmed full-year revenue guidance. Because so much value sits in a single growing product plus a late-stage pipeline candidate, the market cap reflects expectations for peak ORLADEYO sales and navenibart success as much as trailing figures.

CSL. Carlisle trades around a low-20s trailing P/E, roughly in line with its own long-term historical median and typical for a high-margin, cash-generative industrial. Because a large part of its earnings power comes from resilient re-roofing demand and steady margin expansion, investors tend to focus on adjusted EBITDA margin, free cash flow, and the pace of buybacks rather than raw revenue growth, which can be lumpy with weather and construction cycles. The Q1 2026 revenue dip was driven largely by poor winter weather that limited roofing installation, while margins still expanded and management reaffirmed full-year guidance for low-single-digit revenue growth.

Headline figures (approximate, JUNE 2026): BCRX shows revenue (ttm) ~$630M, q1 2026 total revenue ~$156M, q1 2026 orladeyo revenue ~$148M (up ~11% YoY), 2026 orladeyo guidance ~$625M to $645M; CSL shows revenue (ttm) ~$5.0 billion, q1 2026 revenue ~$1.05 billion (down ~4% year over year), q1 2026 adjusted eps ~$3.63 (up ~1% year over year), q1 2026 adjusted ebitda margin ~22.3% (up ~50 bps).

BCRX and CSL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCRX and CSL exposure against your real portfolio. It is not an investment adviser.